Auranofin treatment in early rheumatoid arthritis may postpone early retirement. Results from a 2-year double blind trial.
The effect of early vs delayed initiation of slow acting antirheumatic drug (SAARD) therapy on the ability to maintain regular work, was evaluated in 83 patients with early rheumatoid arthritis (RA) in a placebo controlled, double blind 24-month study. The estimated probability to maintain working ability was higher in the early treatment group, especially during the second study year. Predicting factors were age, type of work, degree of disability and number of swollen joints. Despite the difficulties in interpreting the results due to the complexity of the underlying socioeconomical and labor market situation, the study supports early treatment in RA with regard to the maintenance of normal life.
Department of Social Medicine, Karolinska Institute, Huddinge University Hospital Sweden.
G
G
Borg
E
E
Allander
E
E
Berg
U
U
Brodin
A
A
From
L
L
Trang
D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000503:physiopathology; D001310:Auranofin / Q000627:therapeutic use*; D004185:Disability Evaluation; D004311:Double-Blind Method; D005544:Forecasting; D006801:Humans; D008962:Models, Theoretical; D012179:Retirement; D013997:Time Factors
D001310:Auranofin